Indications of Brinzopt 5 ml Ophthalmic Suspension

Brinzopt Sterile Ophthalmic Suspension is indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma.

Pharmacology of Brinzopt 5 ml Ophthalmic Suspension

Carbonic anhydrase (CA) is an enzyme that can be found in a variety of bodily tissues, including the eye. It catalyzes the reversible reaction of carbon dioxide hydration followed by carbonic acid dehydration. Carbonic anhydrase II (CA-II), which is present mostly in red blood cells but also in other tissues, is the most active isoenzyme. Carbonic anhydrase inhibition in the ciliary processes of the eye reduces aqueous humor secretion, likely by reducing the production of bicarbonate ions and thereby sodium and fluid transfer.

Brinzolamide suppresses aqueous humor formation and lowers increased intraocular pressure after topical ocular application. In the etiology of optic nerve injury and glaucomatous visual field loss, elevated intraocular pressure is a major risk factor.

Dosage and Administration of Brinzopt 5 ml Suspension

Instill 1 drop in the affected eye(s) 2-3 times daily. Brinzopt may be used concomitantly with another topical ophthalmic drug to lower intraocular pressure. If more than one topical ophthalmic drug is being used, the drugs should be administered at least ten minutes apart.

Interaction of Brinzopt 5 ml Ophthalmic Suspension

Rare incidences of medication interactions with high-dose salicylate therapy have occurred in patients treated with oral carbonic anhydrase inhibitors. As a result, patients taking Brinzolamide should be aware of the possibility of such medication interactions.

Contraindications

Brinzolamide 1% ophthalmic suspension is contraindicated in patients who are hypersensitive to any component of this product.

Side Effects of Brinzopt 5 ml Ophthalmic Suspension

Reported side effects are blurred vision and bitter, sour, or unusual taste. Other side effects are blepharitis, dermatitis, dry eye, foreign body sensation, headache, hyperemia, ocular discharge, ocular discomfort, ocular keratitis, ocular pain, ocular pruritus, and rhinitis.

Pregnancy & Lactation

Use in pregnancy: Pregnancy category C. There are no adequate and well-controlled studies in pregnant women. Brinzolamide 1% ophthalmic suspension should be used during pregnancy only if the benefit justifies the potential risk to the fetus.

Use in lactation: It is not known whether Brinzolamide 1% ophthalmic suspension is excreted in human milk. So, the lactating mother should discontinue nursing or discontinue the drug, depending upon the importance of the drug to the mother.

Precautions & Warnings

Brinzolamide 1% ophthalmic suspension and its metabolite are excreted predominantly by the kidney. So, it is not recommended in severe renal impaired patients.

Brinzolamide 1% ophthalmic suspension has not been studied in patients with hepatic impairment and should be used with caution in such patients.

The concomitant administration of Brinzolamide 1% ophthalmic suspension and oral carbonic anhydrase inhibitor is not recommended due to no additional benefits.

If a hypersensitivity reaction occurs after instillation patients should be advised to discontinue the use of Brinzolamide and consult with physicians.

Therapeutic Class

Drugs for miotics and glaucoma

Storage Conditions

Store at room temperature and keep away from direct sunlight. Do not let the dropper tip come into contact with any surface. It’s best if the contents aren’t used for more than four weeks after the bottle is initially opened. Protect yourself from the cold.

Pharmaceutical Name of Brinzopt 5 ml Ophthalmic Suspension

Aristopharma Ltd

Generic of Brinzopt 5 ml Ophthalmic Suspension

Brinzolamide